GWGoro Watanabe

Goro Watanabe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Goro Watanabe has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pancreatic cancer accompanied by a moderate-sized pseudocyst with extrapancreatic growth

    by Yu Ohkura, Kazunari Sasaki, Masamichi Matsuda, Masaji Hashimoto, Takeshi Fujii, Goro Watanabe

    Pancreatic cancer accompanied by a moderate-sized pseudocyst with extrapancreatic growth is extremely rare. Diagnosis of pancreatic cancer on preoperative imaging is difficult when the pancreatic parenchyma is compressed by a pseudocyst and becomes unclear. Despite advances in imaging techniques, accurate preoperative diagnosis of cystic lesions of the pancreas remains difficult. In this case, it was challenging to diagnose pancreatic cancer preoperatively as we could not accurately assess the pancreatic parenchyma, which had been compressed by a moderate-sized cystic lesion with extrapancreatic growth. A 63-year-old woman underwent investigations for epigastric abdominal pain. She had no history of pancreatitis. Although we suspected pancreatic ductal carcinoma with a pancreatic cyst, there was no mass lesion or low-density area suggestive of pancreatic cancer. We did not immediately suspect pancreatic cancer, as development of a moderate-sized cyst with extrapancreatic growth is extremely rare and known tumor markers were not elevated. Therefore, we initially suspected that a massive benign cyst (mucinous cyst neoplasm, serous cyst neoplasm, or intraductal papillary mucinous neoplasm) resulted in stenosis of the main pancreatic duct. We were unable to reach a definitive diagnosis prior to the operation. We had planned a pancreaticoduodenectomy to reach a definitive diagnosis. However, we could not remove the tumor because of significant invasion of the surrounding tissue (portal vein, superior mesenteric vein, etc.). The fluid content of the cyst was serous, and aspiration cytology from the pancreatic cyst was Class III (no malignancy), but the surrounding white connective tissue samples were positive for pancreatic adenocarcinoma on pathological examination during surgery. We repeated imaging (CT, MRI, endoscopic ultrasound, etc.) postoperatively, but there were neither mass lesions nor a low-density area suggestive of pancreatic cancer. In retrospect, we think that the slight pancreatic duct dilation was the only finding suggestive of pancreatic cancer. It is difficult to diagnose pancreatic cancer with pseudocyst preoperatively. If a pancreatic cyst is found in patients who had normal tumor marker levels or no history of pancreatitis, we should always consider the possibility of pancreatic cancer. In such cases, slight pancreatic duct dilation may be a diagnostic clue.


    • 1 March 2015
      • p. 173-6

    [Palliative surgical bypass surgery for patients with pancreatic cancers].

    by Masamichi Matsuda, Goro Watanabe, Masaji Hashimoto

  • Implication of an extremely high preoperative alpha-fetoprotein value (>4,000 ng/mL) for the long-term outcomes of hepatectomy for resectable hepatocellular carcinoma

    by Kazunari Sasaki, Masamichi Matsuda, Yu Ohkura, Yusuke Kawamura, Masafumi Inoue, Masaji Hashimoto, Kenji Ikeda, Hiromitsu Kumada, Goro Watanabe


    • 1 July 2013
      • Vol. 40  (7) , 881-5

    [A retrospective study of UFT and oral leucovorin combination adjuvant chemotherapy for patients over 76 years old with stage III colon cancer].

    by Kenji Tomizawa, Yutaka Hanaoka, Shigeo Toda, Jin Moriyama, Shuichiro Matoba, Hiroya Kuroyanagi, Masaji Hashimoto, Harushi Udagawa, Goro Watanabe

    To perform a retrospective analysis of UFT and oral leucovorin combination adjuvant chemotherapy for Stage III colon cancer patients over 76 years old, in order to evaluate both treatment efficacy and toxicity. Between 2002 and 2011, 333 Stage III colon cancer patients had surgery performed in our institute, and we studied 25 of them on our chemotherapy regimen. Patients'median age was 78 years old, with 12 men and 13 women. Of all the patients, 19 had Stage IIIa and 6 had Stage IIIb. The 3-year disease-free survival rates for Stage III and Stage IIIa patients were 65. 1% and 83. 1%, respectively, and the 3-year overall survival rate for Stage III was 79. 9%. With regard to toxicity, liver function disorder was observed in 8% of the patients, being the adverse event that occurred the most, but there was no Grade 3 or 4 toxicity. UFT and oral leucovorin combination adjuvant chemotherapy for Stage III colon cancer patients over 76 years showed a good response, especially for Stage III a.

  • Factors associated with early cancer‐related death after curative hepatectomy for solitary small hepatocellular carcinoma without macroscopic vascular invasion

    by Kazunari Sasaki, Masamichi Matsuda, Yu Ohkura, Yusuke Kawamura, Masafumi Inoue, Masaji Hashimoto, Kenji Ikeda, Hiromitsu Kumada, Goro Watanabe

    Background Unexpected early cancer‐related death (ECRD) within 2 years due to recurrence after curative hepatectomy for solitary small ( 3 cm and elevation of tumor marker level were independent predictors of ECRD. In the analysis with all variables, excessive intraoperative blood loss, poor differentiation, and microscopic vascular invasion were predictors of ECRD. In the recurrence patterns, 79% of ECRD presented as advanced (four or more lesions) or extra‐hepatic recurrence, whereas these accounted for 18% in the non‐ECRD. Conclusion Excessive blood loss during the operation and histopathological findings of microscopic vascular invasion and poor differentiation are predictive factors of cancer‐related death within 2 years of a hepatectomy for SSHCC.


  • Clinical significance of hepatectomy for primary biliary cirrhosis patients with hepatocellular carcinoma: Report of a single center case series and review of the published work

    by Kazunari Sasaki, Masamichi Matsuda, Yu Ohkura, Yusuke Kawamura, Masafumi Inoue, Yoshiyuki Suzuki, Masaji Hashimoto, Kenji Ikeda, Hiromitsu Kumada, Goro Watanabe

    Aim Hepatectomy for hepatocellular carcinoma (HCC) in patients with primary biliary cirrhosis (PBC) has seldom been reported, and the clinical significance of this procedure remains unclear, although HCC has often been observed in end‐stage PBC patients. Methods To understand the characteristics of hepatectomy on HCC in PBC patients, we examined seven cases at our institute, as well as 22 reported hepatectomy cases in the English‐language and Japanese published work. Furthermore, to assess the treatment efficacy of hepatectomy for HCC in PBC patients, we compared these patients with viral hepatitis patients who underwent hepatectomies at our institute during the same period. Results In the review of 29 cases, more than 70% of the patients were aged over 65 years, and the mean Mayo risk score was low at 5.17. The resected tumors were mainly solitary (79%), and the median maximum tumor size was 37 mm. Approximately two‐thirds of the patients met the Milan criteria. In the comparison between the PBC and viral hepatitis cases, there were no differences in the postoperative prognoses, although the tumor size was greater in the PBC cases. Conclusion Hepatectomy for HCC in selected PBC cases is a feasible and potentially curative treatment option, similar to hepatectomy for HCC in viral hepatitis patients. This procedure is particularly useful for patients with preserved liver function who are not ideal candidates for liver transplantation.


    • 1 April 2012
      • Vol. 39  (4) , 571-5

    [A retrospective study of UFT and oral leucovorin plus PSK combination adjuvant chemotherapy in patients with stage III colon cancer].

    by Kenji Tomizawa, Tsutomu Kumamoto, Yutaka Hanaoka, Shigeo Toda, Jin Moriyama, Shuichiro Matoba, Hiroya Kuroyanagi, Masaji Hashimoto, Harushi Udagawa, Goro Watanabe, et al.

    To perform a retrospective analysis of UFT and oral leucovorin plus PSK combination adjuvant chemotherapy for stage III colon cancer in order to evaluate both treatment efficacy and toxicity. Between 2003 and 2009, 273 stage III colon cancer patients underwent surgery in our institute, and we studied 156 of them. Patients' median age was 72 years old; 87 men and 69 women. Of all patients, 119 had stage IIIa and 37 had stage IIIb. The 3-year disease, free survival rates for stage III, stage IIIa and stage IIIb patients were 73. 9%and 80. 6%and 51. 4%, respectively, and the 3-year overall survival rates for stage III was 97. 6%. With regard to toxicity, liver function disorder was observed in 9. 6%of the patients as the most frequent adverse event, but there was no grade 3 or 4 toxicity. UFT and oral leucovorin plus PSK combination adjuvant chemotherapy for stage III colon cancer showed a good response especially for stage III a.

    • 10 March 2012
      • Vol. 13  (2) , 235-8

    Elevation of pancreatic enzymes in gallbladder bile associated with heterotopic pancreas. A case report and review of the literature.

    by Asahi Sato, Masaji Hashimoto, Kazunari Sasaki, Masamichi Matsuda, Goro Watanabe

    This is the first report associating heterotopic pancreas in the gallbladder and elevated pancreatic enzymes in bile. A 60-year-old woman underwent abdominal ultrasonography at a medical check-up, revealing a nodular protrusion at the neck of the gallbladder. It seemed likely to be a lymph node, but we could not exclude the possibility of gallbladder cancer. In order to make a correct diagnosis, laparoscopic cholecystectomy was successfully performed. Pathological examination revealed heterotopic pancreatic tissue in the gallbladder wall. In addition, we detected elevated levels of amylase and lipase in gallbladder bile. Preoperative diagnosis of heterotopic pancreas in the gallbladder is difficult. However, an increase of pancreatic enzymes in gallbladder bile may potentially play an important role in the occurrence of acalculous cholecystitis and biliary cancer. We need more accumulation of cases to know the true significance of this anomaly.


  • Open Access

    Long-term Survival of a Case of Myxofibrosarcoma with 4 Episodes of Recurrence and Resection

    by Akihiko Shimomura, Masaji Hashimoto, Jin Moriyama, Shuichiro Matoba, Goro Watanabe, Kenichi Ohashi

    粘液線維肉腫(Myxofibrosarcoma;以下,MFSと略記)は中高年の四肢に好発する軟部肉腫であり,後腹膜原発はまれである.MFSに対する化学療法や放射線療法の有効性は確立されておらず,初回手術の際に根治的切除できなければ局所再発を繰り返す例や遠隔転移を来す例が少なくない.症例は58歳男性.右腸腰筋原発のMFSに対し前医で腫瘍切除+右腸腰筋合併切除を施行された.その1年5か月後に局所再発を来し当科紹介受診,腫瘍摘出術+右腎・尿管・腸腰筋合併切除施行した.さらに2年9か月後に腫瘍摘出+右半結腸合併切除,3年5か月後に腫瘍摘出+右腸腰筋・回腸合併切除,4年5か月後に腫瘍摘出+腸腰筋・空腸・胆囊合併切除と計4回の再発・再手術を繰り返した.現在,初回手術より10年,最後の腫瘍切除術より5年経過するが再発の兆候なく生存中である.


    • 18 March 2011
      • Vol. 57, 1087-9

    Superior mesenteric vein resection without reconstruction in pylorus-preserving pancreatoduodenectomy for pancreatic head cancer.

    by Masaji Hashimoto, Mikio Makuuchi, Masamichi Matsuda, Goro Watanabe

    The prognosis of pancreatic cancer is poor, even in resectable patients. The reason for this poor prognosis is partly due to local invasion of the tumor into the tissues around the pancreas. Pancreatic head cancer usually invades the mesentericoportal veins, so the combined venous resection is usually performed during pancreatoduodenectomy for the purpose of obtaining a negative surgical margin. We performed pancreatoduodenectomy for lower pancreatic head cancer together with superior mesenteric vein resection without reconstruction in two patients, after confirming adequate portal venous flow and small intestinal congestion, This is the first report of pancreatoduodenectomy combined with superior mesenteric vein resection without reconstruction for the purpose of obtaining a wide surgical margin.